Therapy of clinical stage IIA and IIB seminoma: a systematic review - Top-Institutions - MDSpire

Therapy of clinical stage IIA and IIB seminoma: a systematic review

  • By

  • Julia Heinzelbecker

  • Stefanie Schmidt

  • Julia Lackner

  • Jonas Busch

  • Carsten Bokemeyer

  • Johannes Classen

  • Annette Dieing

  • Oliver Hakenberg

  • Susanne Krege

  • Alexandros Papachristofilou

  • David Pfister

  • Christian Ruf

  • Hans Schmelz

  • Heinz Schmidberger

  • Rainer Souchon

  • Christian Winter

  • Friedemann Zengerling

  • Sabine Kliesch

  • Peter Albers

  • Christoph Oing

  • November 15, 2021

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Radiation Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Urologic Oncology
    • Radiation Oncology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Urologic Oncology
    • Radiation Oncology
    • Medical Oncology

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urologic Oncology
    • Medical Oncology
    • Radiation Oncology

  • #5

    Charité – Universitätsmedizin Berlin
    Charité – Universitätsmedizin Berlin

    Berlin, Berlin

    Key Differentiators

    • Urologic Oncology
    • Radiation Oncology
    • Medical Oncology

Original Source(s)

Therapy of clinical stage IIA and IIB seminoma: a systematic review

  • by Julia Heinzelbecker, Stefanie Schmidt, Julia Lackner, Jonas Busch, Carsten Bokemeyer, Johannes Classen, Annette Dieing, Oliver Hakenberg, Susanne Krege, Alexandros Papachristofilou, David Pfister, Christian Ruf, Hans Schmelz, Heinz Schmidberger, Rainer Souchon, Christian Winter, Friedemann Zengerling, Sabine Kliesch, Peter Albers, Christoph Oing

  • November 15, 2021

Related Content

Optimizing Outcomes: How Multidisciplinary Approaches Improve Prostate Cancer Survival Rates

Prostate cancer management has evolved significantly over the years, propelled by groundbreaking diagnostics and advancements in treatment modalities.

  • by

  • March 18, 2024

  • 4 min
Beyond Treatment Volume: When Pelvic Radiotherapy May Still Matter in High-Risk Localised Prostate Cancer

Prostate Cancer Conference Highlights from ASCO GU 2025

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. This video highlights updates in mCRPC and oligometastatic prostate cancer trials.

  • March 3, 2025

  • 1 min